Watertown, United States
Werewolf Therapeutics is a biotechnology startup, founded in 2017 and based in the United States. The company is driven by the mission of advancing a pipeline of next-generation, transformative immuno-stimulatory medicines for cancer patients. Their slogan, "Advancing a pipeline of next generation, transformative immuno-stimulatory medicines for cancer patients," underscores their commitment to leveraging innovative solutions in the field of immuno-oncology.
Their recent $50.00M post-IPO secondary investment on 10 May 2022 signifies a significant milestone for the company, demonstrating the confidence of investors in their vision and capabilities. While the details of the specific investors involved in this round are not provided, the substantial investment amount attests to the level of interest Werewolf Therapeutics has garnered in the investment community.
As the company continues to progress in the advancement of their pipeline, this recent investment serves as a testament to their potential impact in the biotechnology sector and their dedication to improving treatment options for cancer patients.
